- Home
- TBLAW vs TNGX Comparison
TBLAW vs TNGX Comparison
Compare TBLAW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLAW
- TNGX
- Stock Information
- Founded
- TBLAW N/A
- TNGX 2014
- Country
- TBLAW Israel
- TNGX United States
- Employees
- TBLAW 1900
- TNGX N/A
- Industry
- TBLAW Computer Software: Programming Data Processing
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TBLAW Technology
- TNGX Health Care
- Exchange
- TBLAW Nasdaq
- TNGX Nasdaq
- Market Cap
- TBLAW N/A
- TNGX 735.0M
- IPO Year
- TBLAW N/A
- TNGX N/A
- Fundamental
- Price
- TBLAW $0.15
- TNGX $6.64
- Analyst Decision
- TBLAW
- TNGX Strong Buy
- Analyst Count
- TBLAW 0
- TNGX 8
- Target Price
- TBLAW N/A
- TNGX $15.14
- AVG Volume (30 Days)
- TBLAW N/A
- TNGX 885.7K
- Earning Date
- TBLAW N/A
- TNGX 11-06-2024
- Dividend Yield
- TBLAW N/A
- TNGX N/A
- EPS Growth
- TBLAW N/A
- TNGX N/A
- EPS
- TBLAW N/A
- TNGX N/A
- Revenue
- TBLAW N/A
- TNGX $42,509,000.00
- Revenue This Year
- TBLAW N/A
- TNGX $18.15
- Revenue Next Year
- TBLAW N/A
- TNGX N/A
- P/E Ratio
- TBLAW N/A
- TNGX N/A
- Revenue Growth
- TBLAW N/A
- TNGX 26.16
- 52 Week Low
- TBLAW N/A
- TNGX $6.33
- 52 Week High
- TBLAW N/A
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- TBLAW N/A
- TNGX 37.15
- Support Level
- TBLAW N/A
- TNGX $6.83
- Resistance Level
- TBLAW N/A
- TNGX $7.47
- Average True Range (ATR)
- TBLAW 0.00
- TNGX 0.37
- MACD
- TBLAW 0.00
- TNGX 0.11
- Stochastic Oscillator
- TBLAW 0.00
- TNGX 27.31
About TBLAW Taboola.com Ltd. Warrant
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.